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Aim: The present study was designed to investigate whether the three-apolipoprotein (AI,
B, E) gene polymorphisms were related to alter their plasma protein levels and hence
associated to coronary artery disease (CAD).
Methods: We determined distribution of MspI apo AI, EcoRI apo B, HhaI apo E gene poly-
morphisms, plasma apolipoproteins and lipids levels among 150 patients having CAD
admitted to the Department of Cardiology, N.R.S. Medical College & Hospital, Kolkata, India
during June 2010eJune 2012 and 150 age sex matched healthy controls.
Results: We found that ApoAI concentration of studied population was significantly
different in each genotypes of 75 G/A apo AI (p < 0.0001) gene polymorphism. A significant
association was found in multivariate analysis for the genotypes with apo E4 allele [odds
ratio (OR): 3.639; 95% confidence interval (CI): 1.019e12.995, p ¼ 0.040] with four conven-
tional risk factors (i.e. smoking, low-density lipoprotein, ApoAI and ApoB) with CAD. In
contrast E2 allele has reverse effect, but the genotypes with apo E2 allele was no longer
significant in the multivariate model (OR: 1.788; 95% CI: 0.400e8.001, p ¼ 0.447) where as
being significant in univariate analysis (OR: 0.219; 95% CI: 0.087e0.552, p ¼ 0.001).
Conclusions: Our findings suggest that the polymorphisms apo AI MspI and apo B EcoRI do not
seem to affect CAD. But the genotype with E4 allele of apo E gene independent of other risk
factors is associated with this disease.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction of premature CAD in Asian Indians settled in widely differentThe high tendency to develop premature and accelerated CAD
in Asian Indians is only partially explained by the presence of
conventional risk factors such as insulin resistance, abdom-
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The nutritional variations have led to increased intake of fat
and cholesterol contents, which has gradually increased
serum lipid levels. Disorders of lipid metabolism such as
elevated serum levels of total cholesterol (TC),3 triglycerides
(TGs),4 low-density lipoprotein cholesterol (LDL-c),5 apolipo-
protein (Apo) B,6 or low levels of high-density lipoprotein
cholesterol (HDL-c) and ApoAI7 have been considered to be
important risk factors in the pathogenesis of atherosclerosis
and coronary artery disease (CAD),8 whereas the influence of
ApoE on serum lipid levels is often suggested to have major
implications for the risk of CAD.9
The protective effect of HDL-c andApoAI on the risk of CAD
is mediated mainly through the promotion of cholesterol
efflux from peripheral cells.10 In addition, both HDL-c and
ApoAI may have antioxidant, antithrombotic, and anti-
inflammatory properties, which could have important
antiatherogenic effects.10 The apo AI gene is localized on
chromosomal region 11q23 and is a member of the apolipo-
protein multigene superfamily, which includes genes encod-
ing for exchangeable apolipoproteins like ApoAI, AII, Cs, and
E. The gene has been documented to possess several single
nucleotide polymorphisms (SNPs) out of which 75G/A and
83C/T have been widely studied. The rare allele A (M1) of
the promoter region polymorphism 75G/A has been associ-
ated with raised HDL-c levels and this raised level is supposed
to be due to its effects on apo AI gene transcription and
increase in ApoAI concentrations. In comparison to 75G/A
polymorphism, the mutant T allele (M2) of 83C/T
polymorphism has been associated with even higher rises in
HDL-c levels.10
Apolipoprotein (Apo) B-100 is the principal protein compo-
nent of LDL. The interaction of ApoB-100 with LDL receptors
mediates the uptake of LDL from the liver and peripheral cells;
hence Apo B-100 plays an important role in cholesterol ho-
meostasis.11 The apo B gene is localized on chromosome 2, and
the complete structure of the human apo B-100 gene has been
elucidated.12 Several restriction fragment length poly-
morphisms (RFLPs) of the apo B gene have been described,
including Xba1,13EcoR1,14 and insertion/deletion (ins/del) poly-
morphism of the signal peptide region.15 The EcoRI poly-
morphism (rs1042031) caused by a single nucleotide shift from
G toA at nucleotide position 4154 present in exon 29 of the gene
results in anaminoacid change, Glu/ Lys. This polymorphism
affects the binding of LDL to the LDL receptor leading to
decreased catabolismof LDLparticles containingmutant alleles
thus contributing to an increase in LDL-c levels.15
Apolipoprotein E (ApoE) is a protein that is incorporated
into serum lipoproteins and directs their catabolism via
binding to receptors. ApoE modulates the catabolism of
triglyceride-depleted remnants of chylomicrons (CM) and very
low-density lipoprotein (VLDL). The apo E gene, together with
the apo CI, and apo CII genes, forms a gene cluster on the long
arm of chromosome 19 (19q13.2).16 apo E is polymorphic with
three common alleles (E2, E3, and E4) coding for 3 isoforms (E2,
E3, and E4), which produce 3 homozygous (E2/E2, E3/E3, and
E4/E4) and 3 heterozygous (E2/E3, E2/E4 and E3/E4) phenotypes
in the human population.17 The frequencies of the E2 (112cys
and 158cys), E3 (112cys and 158arg), and E4 (112arg and 158arg)
alleles are relatively constant in adult Caucasians (8%, 78%,and 14%, respectively).18 However, the frequencies of these
alleles in other populations are not identical. Allelic differ-
ences at the apo E gene locus determine about 16% of the ge-
netic variance in the concentrations of LDL-c.19 Thus subjects
with the genotypes E3/E2 and E4/E2 have 20% lower and those
with genotype E4/E3 have 10% higher levels of LDL-c
compared with subjects with genotype E3/E3.20 The inci-
dence of CAD is increasing in India, especially in the younger
population. Hence, it is important to delineate risk factors for
CAD in Indians. No data are available for the relationship be-
tween apolipoprotein gene polymorphism and their plasma
levels or other CAD risks factors in inhabitants of Asian Indian
population in eastern part of India. We therefore hypothe-
sized that genetic factor of these three apolipoprotein gene
(apo AI, apo B and apo E) polymorphisms are important de-
terminants of CAD in this population. To test this hypothesis,
we studied all three-gene polymorphisms in patients with
CAD and compare them with age sex matched healthy
controls.2. Methods
2.1. Study subjects
The study group was admitted to the Department of Cardiol-
ogy unit at NRS Medical College and Hospital, Kolkata, India
who had been diagnosed to have ischemic heart disease. The
diagnosis was based on the complete physical and clinical
examination of patients with typical angina and electrocar-
diographic study, tread-mill test, stress echo and echocar-
diographic evidence of ischemia or infarction. For the present
study, only patients with ischemic heart disease were
included, while patients with Alzheimer’ disease, pulmonary,
renal, hepatic diseases, cardiomyopathy and congestive heart
failure and those taking any lipid lowering drugs were
excluded.
The controls comprised the spouses, neighbors, and people
from same work place of the patients, with the same socio-
cultural background, in whom the clinical history, the objec-
tive search for signals of CAD, and the electrocardiographic as
well as echocardiographic examinations did not suggest the
presence of that disease. In the present study, evaluation of
the contribution of confounding risk factors of the develop-
ment of CAD was based on the individual’s personal history
findings.
2.2. Biochemical analysis
5 ml blood specimens were drawn after a 12 h overnight
fast into EDTA-containing tubes. The plasma was separated
after centrifugation at 2500 rpm for 10 min and was sent
for biochemical analysis and used within 24 h for lipid ana-
lyses. TC, HDL-c and TG levels were measured by means of a
semi-auto analyzer (Merck Ltd., India) using standard enzy-
matic methods. LDL-c levels were calculated using the Frie-
dewald formula. HDL-c was determined after precipitation of
the apolipoprotein (Apo) B-containing lipoproteins by phos-
photungstate/magnesium chloride. Apolipoprotein AI, B, and
E were determined by immunoturbidimetry method using
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 6 5 8e6 6 5660auto N “DAIICHI” reagent and for standard measurement
using Apo auto N “DAIICHI” calibrator.2.3. DNA extraction
Genomic DNA was isolated using the phenol chloroform
method. Extracted DNA was dissolved in 1 TE buffer after
air-drying of ethanol and was stored at 4 C until further
analysis. All information regarding the volunteers and the
DNA samples were saved onto the laboratory database after
they were assigned sequential code numbers.2.4. apo AI MspI polymorphisms
The forward primer to amplify the 433-bp fragment at the 5
0
end of the apo AI gene was 50-AGGGACAGAGCTGATCC
TTGAACTCTTAAG-30 with the reverse primer being 50-
TTAGGGGACACCTAGCCCTCAGGAAGAGCA-30. Polymerase
chain reaction (PCR) was performed in a volume of 25 ml
containing 200 ng genomic DNA. The amounts of Mg2þ, dNTP,
and DNA polymerase (Bangalore Genei, India) used in each
reaction were 1.5 mM, 200 mM, and 1 U, respectively. The
thermal cycles started with 94 C for 4 min and were followed
by 35 cycles of 94 C for 30 s, 55 C for 30 s, and 72 C for 30 s. A
total volume of 20 ml containing 20 U MspI was added directly
to the PCR product and digested at 37 C overnight. After
electrophoresis, the digested productswere visualized on a 9%
polyacrylamide gel with ethidium bromide staining.
There are 3 MspI restriction sites within the region ampli-
fied by PCR located at 75, þ37, and þ83 bp (Fig. 1). The ge-
notypes of the 75-bp substitution are GG, GA, and AA.21 Both
the G-to-A substitution at 75 bp and T-to-C and/or G-to-A
substitutions atþ83 bp result in a loss ofMspI restriction sites,
which were detected simultaneously by a single MspI diges-
tion after PCR. The putative genotypes at75 bp are defined as
M1þ/þ (GG) for the presence of MspI sites in both alleles (þ in-
dicates the presence and eindicates the absence of the MspI
restriction site), M1/(AA) for the absence of the site in both
alleles, and M1þ/(GA) for a heterozygote. The putative geno-
types at þ83 bp are M2þ/þ, M2þ/, and M2/.2.5. apo B EcoRI polymorphism
The following primer pair forward-50-CTGAGAGAA
GTGTCTTCGAAG-30 and reverse 50-CTCGAAAGGAAGTFig. 1 e MspI restriction sites at the 50-end of the apo AI
gene amplified by PCR. M* [ polymorphic MspI restriction
site. The relevant fragment sizes with and without the
base substitutions are indicated in each box
(Supplementary Figure A).GTAATCAC-30 was used to amplify a region in the apo B gene.
Each amplification reaction contained 300 ng DNA, 25 pmol of
each primer, and 0.625 unit of Taq DNA polymerase in a final
volume of 25 ml. The polymerase chain reaction procedure
consisted of an initial denaturation step at 94 C for 5 min,
followed by 40 cycles of denaturation at 94 C for 5 s, annealing
at 58 C for 10 s, and extension at 72 C for 30 s.This was fol-
lowed by a final extension of 7 min at 72 C and the PCR
product was digested with EcoRI at 37 C overnight. The ge-
notypes were determined by running the digested product in
2% agarose gel. Rþ designates the presence of restriction site
and R indicates absence of site for the enzyme EcoRI. The
total PCR product was of 480 bp size, which was digested with
EcoR1 into two fragments of 253 bp and 227 bp in the presence
of the cutting site (Eþ) (Supplementary Figure B).
2.6. apo E HhaI polymorphism
The 227 bp sequence of apo E was amplified by PCR in a DNA
Thermal Cycler (Perkin Elmer Cetus 2400) using oligonucleo-
tide primers forward (50-TCCAAGGAGCTGCAGGCGGCGCA-30)
and reverse (50-ACAGAATTCGCCCCGGCCTGGTACACTGCCA-
30). Each amplification reaction contained 250 ng of leukocyte
DNA, 15 pmol of each primer, 200 mM dNTP 10% dimethyl
sulfoxide, and 0.625 unit of Taq DNA polymerase in a final
volume of 30 ml. Each reaction mixture was heated at 95 C for
1min for denaturation, and subjected to 35 cycles of annealing
(65 C for 25 s) and extension (72 C for 50 s). After PCR
amplification, 20 units of HhaI (Roche) were added to 20 ml PCR
product and digested at 37 C for 3 h. The digested productwas
loaded onto a 12% nondenaturing polyacrylamide gel and
electrophoresed for 2 h at constant voltage. The gel was
stained with ethidium bromide for 10 min and visualized
under UV illumination. 227 bp amplicon digested with HhaI
resulted in five genotypes, viz., E2/E2 (91, 81, 21, 18, 16), E3/E3
(91, 48, 33, 21, 18, 16), E4/E4 (72, 48, 33, 21, 19, 18, 16), E2/E3 (91,
81, 48, 33, 21, 18, 16), and E3/E4 (91, 72, 48, 33, 21, 19, 18, 16)
(Supplementary Figure C).
2.7. Statistical analysis
The data were recorded on a pre-designed worksheet and
managed with Microsoft Excel software. Data entry was
double-checked. After confirming the normality aspects of the
quantitative variables, descriptive statistics were computed
using mean and standard deviation (SD). For qualitative vari-
ables, proportions were summarized. Student’s t- test was
applied to compare the mean values of quantitative variables
among CAD patients and healthy controls. Frequency of allele
is calculated as number of observation at the given allele
divided by total number of observation. Associations of other
categorical variables with CAD were assessed by c2 test or
Fisher’s exact test, whichever was applicable. At the next
stage of analysis, all the variables significantly associatedwith
CAD were included in the logistic regression analysis after
quantifying the associations by computing the unadjusted
odds ratio for each variable. One way analysis of variance
(ANOVA) was performed to test the null hypothesis of equality
of apolipoprotein levels among the apolipoprotein genotype
groups. All calculations were performed using SPSS, version
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i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 6 5 8e6 6 5 66110 (SPSS, Chicago). Association of other categorical having
p< 0.05was considered as statistically significant. Assuming a
2-sided test with a ¼ 0.05, power was calculated for the
referent genotype compared with the other genotypes. The
purpose of this was that the power validates the discovered
associations because type II error is an important consider-
ation herein.M1+/+ M1+/- M1-/-
0
Ap
Fig. 2 e Apolipoprotein AI (ApoAI) concentration of study
population according to the L75MspI restriction site
genotypes. Subjects with M1D/D, M1D/-and M1L/L
genotypes had mean ApoAI of 121.84, 115.53 and
146.84 mg/dl, respectively. The p-value is for comparison
of the three genotypes (one way ANOVA). Data are shown
as mean ± s.d.3. Results
One hundred and fifty patients with angiographically proven
CAD (126 males, 24 females) and one hundred fifty normal
controls (129males and 21 females) were evaluated. Themean
age of the patients was 54.68  8.84 years, while that of the
controls was 52.76  10.16 years. Smoking was highly preva-
lent in the group with CAD as compared to control group.
Significantly higher mean concentrations of TC, LDL-c and TG
(p< 0.0001) were observed in the CAD patients compared with
the normal subjects, but the mean value of HDL-c was
significantly lower in CAD patients than controls. Among the
apolipoproteins, mean value of ApoB was higher in patients
compared to controls and value of ApoAI was just reverse of it
and both the valueswere statistically highly significant, on the
other hand, mean value of ApoE was similar in patients and
controls and the value was statistically insignificant (Table 1).
ApoAI plasma concentration in relation to the75G/AMspI
restriction site genotype in the studied population is shown in
Fig. 2. Individuals with the M1þ/þ and M1þ/-genotypes had a
mean ApoAI concentration 1.2 times and 1.27 times, respec-
tively, lower than the mean ApoAI concentration of M1/
genotypes (p < 0.0001 for the difference genotypes).
In contrary, there was no such mean plasma ApoAI, ApoB
and ApoE concentration difference in each genotype of apo AI
þ83MspI, apo B EcoRI and apo E HhaI restriction site genotypes,
gene polymorphism (p ¼ 0.495, Fig. 3; p ¼ 0.05, Fig. 4; p ¼ 0.403,
Fig. 5, respectively).
The association of different apolipoprotein genotypes
among CAD patients is shown in Table 2. There was no such
association found among apo AI and apo B genotype. Among
the apo E genotype the E3/E4was extensivelymore common in
patients compared to the healthy control group (OR: 7.178,
95% CI: 3.093e16.657, p < 0.0001) whereas, the E2/E3 genotype
was more common in the control group (OR: 0.253, 95% CI:
0.091e0.700, p ¼ 0.01).Table 1 e Carrier frequencies and mean (SD) of baseline chara
Risk factor Control (n
Age/years 52.76 (1
Sex (male/female) 129/21
Smoker 39 (2
Total cholesterol mg/dl 153.82 (3
Low-density lipoprotein cholesterol mg/dl 89.41 (3
High-density lipoprotein cholesterol mg/dl 33.05 (8
Triglycerides mg/dl 150.09 (5
ApoAI mg/dl 130.39 (2
ApoB mg/dl 94.63 (1
ApoE mg/dl 4.08 (0The allele frequencies of both patients and controls were
found to be in HardyeWeinberg equilibrium (p > 0.05). Table 3
shows the allele frequency of different apolipoprotein genes.
In this analysis, we have not found any statistically significant
difference in allele frequency among apo AI and apo B gene. On
the contrary, in apo E gene most participants carried at least
one E3 allele, but 2.3% patient and 10% control carried an E2
allele (p ¼ 0.003), while 15%, and 3.7% carried an E4 allele
among patient and control, respectively (p < 0.0001).
Variables showing statistically significant associations
with CAD at p < 0.05 were simultaneously considered in a
multivariate logistic regression model. We identified only five
important predictors were statistically significant in this
model. Among these, predictor presence of apo E4 allele (OR:
3.639, 95%CI: 1.019e12.995; p¼ 0.040) was found superior than
other conventional risk factor i.e. smoker (OR: 0.044, 95% CI:
0.016e0.122; p < 0.0001), LDL-c (OR: 1.046, 95% CI: 1.013e1.079;
p ¼ 0.005), apo AI (OR: 0.923, 95% CI: 0.894e0.953; p < 0.0001)
and apo B (OR: 1.109, 95% CI: 1.062e1.162; p < 0.0001) (Table 4).
For these risk factors, the 95% CIs were wide because of small
sample size.
Power calculation showed that the apo E and apo AI75G/A
gene polymorphism had 99% (p < 0.0001) and 62% (p ¼ 0.039)
respectively statistical power, but the apo B and apo AI þ83C/T
gene polymorphism had showed only 54% (p ¼ 0.067) and 46%cteristics by coronary artery disease (CAD).
¼ 150) CAD (n ¼ 150) p-value
0.16) 54.68 (8.84) Matched
126/24 Matched
6%) 123 (82%) <0.0001
9.83) 195.48 (38.09) <0.0001
1.18) 132.37 (35.52) <0.0001
.03) 29.25 (7.54) <0.0001
5.51) 173.44 (57.45) <0.0001
1.46) 109.73 (23.03) <0.0001
4.39) 110.74 (16.32) <0.0001
.74) 4.05 (0.54) 0.697
E2/E2 E2/E3 E3/E3 E3/E4 E4/E4
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Fig. 5 e Apolipoprotein E (ApoE) concentration of study
population according to the HhaI restriction site genotypes.
Subjects with E2/E2, E2/E3, E3/E3, E3/E4 and E4/E4
genotypes had mean ApoE of 3.77, 4.26, 4.06, 4.02 and
3.83 mg/dl, respectively. The p-value is for comparison of
the three genotypes (one way ANOVA). Data are shown as
mean ± s.d.
Fig. 3 e Apolipoprotein AI (ApoAI) concentration of study
population according to the D83 MspI restriction site
genotypes. Subjects withM2D/D andM2D/L genotypes had
mean ApoAI of 120.53 and 118.07 mg/dl, respectively. The
p-value is for comparison of the three genotypes (one way
ANOVA). Data are shown as mean ± s.d.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 6 5 8e6 6 5662(p ¼ 0.121) respectively, which are statistically inadequate
power in the association studies.4. Discussion
The results of the present study show that plasma TC, TG,
LDL-c and ApoB levels are significantly higher in CAD patients
than in controls, whereas the levels of HDL-c and ApoAI in
CAD patients are significantly lower than controls. These
findings are consistent with those of our previous studies in a
large population.22 The genotype frequencies of apo AI, apo B
and apo E gene polymorphisms and their protein levels along
with different conventional risk factors have been established
for the first time in an Asian Indian population in the eastern
part of India. The apo AI 75G/A polymorphism was found to
be significantly associated with ApoAI levels in this popula-
tion whereas no association was found in þ83C/T poly-
morphism. Therewas no statistically significant change in the
ApoB among different genotypes of apo B EcoRI polymorphismR+/+ R+/-
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Fig. 4 e Apolipoprotein B (ApoB) concentration of study
population according to the EcoRI restriction site
genotypes. Subjects with RD/D and RD/- genotypes had
mean ApoB of 104.44 and 98.17 mg/dl, respectively. The p-
value is for comparison of the three genotypes (one way
ANOVA). Data are shown as mean ± s.d.and also no significant difference was found in plasma levels
of ApoE among the apo E HhaI genotypes.
Elevated levels of HDL-c and ApoAI are associated with
reduced risk of developing CAD, probably because of the
ability of HDL particles to promote cholesterol efflux from the
cells.23 A G-to-A transition in the promoter region of the apo AI
gene is relatively common, occurring in, 20% of normal Cau-
casians, and the frequency of the rare M2 allele (þ83 bp) has
been reported to be 4.1%.24 In the present study, theM1 allele
frequency (29%) and theM2 allele frequency (8%) was greater
than that of reported in previous studies.24 Mechanisms
explaining the relationship of T and/or A substitutions with
increased HDL cholesterol and ApoAI levels are currently
unknown. However, hypomethylation, which occurs in the T
and/or A substitution at the 59 region of the apo AI gene, in-
creases apo AI gene expression.25 Alternatively, the T and/or A
substitutions, which are located in the 50-end leader region of
the ApoAI mRNA, could be important for the initiation of
mRNA translation.26 Matsunaga et al demonstrated that an
AeC substitution at position 27 within TATA box and G to A
substation at position 75 of human apo AI gene were asso-
ciated with reduced ApoAI levels.27 In our study, we also
found that ApoAI concentration is lower in heterozygous
(M1þ/) than any other homozygous population in the75 G/A
MspI restriction site polymorphism. These data suggest that
theM1þ/ and27 AeC substitution had the additive effect for
reduced ApoAI levels. In the present study, the loss of theMspI
site by the C-to-T (þ830 bp) and/or G-to-A (þ84 bp) sub-
stitutions was not associated with ApoAI.
A reasonwhyApoBmay be a stronger predictor of risk than
LDL-c is that ApoB is present not only in LDL but also in VLDL,
intermediate density lipoprotein, and lipoprotein (a). There-
fore, the sum of ApoB concentrations in all atherogenic par-
ticles might be a better risk marker than TC and LDL-c levels
only.6 Absence of an association between EcoR1 poly-
morphism of apo B and plasma ApoB levels is, however,
similar to the observationsmade by other group.28,29 The RFLP
detected with EcoR1 is due to a single base pair change in the
coding region of the gene, which is known to cause an amino
Table 2 e Association of apolipoprotein AI, B and E genotypes among of CAD patients.
Genotype Control, no (%) Patients, no (%) p-value OR 95% CI
apo AI (M1)
M1þ/þ 72 (48%) 69 (46%) Reference
M1þ/ 68 (45%) 76 (51%) 0.356 1.238 0.786e1.949
M1/ 10 (7%) 5 (3%) 0.194 0.483 0.161e1.448
apo AI (M2)
M2þ/þ 126 (84%) 117 (78%) Reference
M2þ/ 24 (16%) 33 (22%) 0.187 1.481 0.827e2.652
apo B (R)
Rþ/þ 102 (68%) 114 (76%) Reference
Rþ/- 48 (32%) 36 (24%) 0.124 0.671 0.404e1.115
apo E
E3/E3 117 (78%) 102 (68%) Reference
E2/E2 6 (4%) 1 (0.67%) 0.092 0.161 0.019e1.355
E2/E3 18 (12%) 5 (3.33%) 0.01 0.253 0.091e0.700
E3/E4 7 (5%) 39 (26%) <0.0001 7.178 3.093e16.657
E4/E4 2 (1%) 3 (2%) 0.654 1.510 0.248e9.170
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 6 5 8e6 6 5 663acid change in the ApoB by itself. apo B R- allele frequency was
found in our population similar in North Indians (0.18) and
Brazilians (0.15).30,31 R- allele frequency in the present study
population was found to be nearly three times than that of
Chinese from Taipei (0.05).32 Hegele and his co-workers also
found a significant correlation between apo B gene poly-
morphisms and CAD, without any significant associationwith
either LDL or VLDL.33 Similar results were reported in a
porcine model of atherosclerosis in which an apo B genetic
variant was associated with atherosclerosis, despite normal
lipid levels.34 Our results show that the apo B gene variations
possibly do not affect the ApoB levels. We speculated that a
mutation in the protein coding region of apo B could affect the
interaction of LDL with monocyte macrophages, endothelial
cells, ground substance, clotting factors, or the immune sys-
tem in a manner that would promote atherogenesis.35 The
present study and other investigators have found that
although CAD patients showed a significantly higher con-
centration of LDL-c than the controls, none of the alleles of the
apo B gene was significantly associated with variation in
concentrations of ApoB in CAD patients or in controls.36
Paulweber et al reported that it is the R- allele that isTable 3 e Frequency distribution of apolipoproteins
alleles.
Alleles Control (n ¼ 150) Patients (n ¼ 150) p-value
apo AI (M1)
M1þ 0.71 0.71 Reference
M1- 0.29 0.29 1.000
apo AI (M2)
M2þ 0.92 0.89 Reference
M2- 0.08 0.11 0.212
apo B (R)
Rþ 0.84 0.88 Reference
R- 0.16 0.12 0.159
apo E
E3 0.862 0.827 Reference
E2 0.100 0.023 0.003
E4 0.037 0.150 <0.0001associated with the risk of CAD. But in our study this associ-
ation is not found.37
The apo E ε2/ε3/ε4 genotypes explain between 10% and 20%
of the total variation of the plasma ApoE concentration in the
population at large.38,39 However, combined linkage and as-
sociation analysis revealed thatz80% of the total variation in
plasma ApoE concentration is determined by genetic fac-
tors.40 But in our study we did not find any correlation be-
tween apo E genotypes and ApoE plasma concentration.
According to Mannila et al the apo E promoter polymorphism
rs769,446 as a functional SNP involved in the regulation of the
plasma ApoE concentration. However, the rs769,446 SNP was
not associated with changes in plasma lipoprotein levels,
indicating that variation in plasma ApoE concentration does
not influence CHD risk41 as has been found in the study. In a
population based study, Venkataramana et al reported that
the allele frequencies in Indian population 85%e92% for E3
allele, 3.9% for E4 allele and 3.5% for E2 allele.42 In the present
study, apo E allele frequencies in the control group of our
population are 3.7%, 86.2% and 10% for E4, E3 and E2, respec-
tively, which are comparable with the study.42 As is shown in
Table 2, the prevalence of E3/E4 genotype was high in patient
group than control subjects (OR: 7.178; 95% CI: 3.039e16.657;
p < 0.0001). This finding suggests that the prevalence of E3/E4
genotype may be risk factors in this complex disease. Differ-
ence in the frequency of reference allele E3 was not statisti-
cally significant in control group when compared to patient
(86.2% vs 82.7%, p ¼ 0.215), while statistical difference was
found between patients and controls with respect to E2 and E4
allele frequency (2.3% vs 10%, p ¼ 0.003, and 14.4% vs 3.6%,
p < 0.0001). Carriers of E4 allele form a high-risk group
showing greater susceptibility to CAD while the E2 allele has
reverse effect. It has been suggested that the E4 allele is
related to HDL-c and LDL-c levels, while the potential anti-
atherogenic of the E2 involving lower levels of LDL-c may be
offset by accumulation of atherogenic large very low-density
lipoprotein cholesterol and remnant rich lipoproteins.43,44
Beyond the effect on lipid metabolism, apo E genotypes may
also affect CAD risk though antioxidative, inflammatory and
immune activities.43,44 In this investigation, we found that
carriers of E4 allele had four fold higher risk of developing CAD
Table 4 e Logistic regression analysis to determine risk factors for CAD.
Variables Unadjusted odds ratio (95% CI) Adjusted odds ratio (95% CI), p-value
smoker 0.077 (0.044e0.134) 0.044 (0.016e0.122), p < 0.0001
TC mg/dl 1.028 (1.021e1.036) 0.995 (0.965e1.025), p ¼ 0.725
LDL-c mg/dl 1.039 (1.029e1.048) 1.046 (1.013e1.079), p ¼ 0.005
HDL-c mg/dl 0.938 (0.909e0.968) 0.989 (0.926e1.055), p ¼ 0.728
TG mg/dl 1.008 (1.003e1.012) 0.999 (0.990e1.009), p ¼ 0.912
ApoAI mg/dl 0.958 (0.946e0.970) 0.923 (0.894e0.953), p < 0.0001
ApoB mg/dl 1.074 (1.053e1.095) 1.109 (1.062e1.162), p < 0.0001
ApoE mg/dl 0.933 (0.658e1.321) e
Genotypes with apo AI M1 allele 1.084 (0.688e1.705) e
Genotypes with apo AI M2 allele 1.481 (0.827e2.652) e
Genotypes with apo B R allele 0.716 (0.428e1.196) e
Genotypes with apo E2 allele 0.219 (0.087e0.552) 1.788 (0.400e8.001), p ¼ 0.447
Genotypes with apo E4 allele 6.092 (2.843e13.056) 3.639 (1.019e12.995), p ¼ 0.040
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 6 5 8e6 6 5664(OR: 3.639, 95% CI: 1.019e12.995; p ¼ 0.040) with smoking, LDL-
c, ApoAI and ApoB but no association were found with TC,
HDL-c, triglycerides and genotypes with apo E2 allele.
The lack of association for apo AI and apo B gene poly-
morphism in our study may be attributed to ethnic variation,
or it may have been limited by its statistical power, and the
current findings cannot definitively exclude a non-significant
association between this polymorphism and CAD because of
inadequate power. The size of the studied population is rela-
tively small, and therefore our findings need to be confirmed
in larger initial test populations or novel genetic epidemio-
logical approaches to extract the genetic contribution to
prevalent phenotypes such as CAD. Finally, we cannot
exclude that the observed associations depend on the effect of
genes.
In conclusion, our results support the notion that a sig-
nificant association of E4 allele is observed with CAD in
addition to the other well known risk factors (smoking, LDL-c
ApoAI and ApoB) and this study shows genotypes with E4
allele is the prominent genetic predictors, for the develop-
ment of CAD in Asian Indian population in Eastern part of
India. These interesting observations should be confirmed in
further large-scale trials in patients with CAD and in other
macrovascular atherosclerotic diseases in Asian Indians.Conflicts of interest
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